Attached files

file filename
EX-99.1 - PRESS RELEASE - BIONOVO INCdex991.htm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

September 23, 2010

Date of Report (Date of earliest event reported)

 

 

BIONOVO, INC.

(Exact Name of Registrant as Specified in Charter)

 

 

 

Delaware   001-33498   20-5526892

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

5858 Horton Street, Suite 400, Emeryville, CA 94608

(Address of Principal Executive Offices) (Zip Code)

(510) 601-2000

(Registrant’s telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 8.01. Other Event.

  On September 23, 2010, Bionovo, Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration accepted the Company’s Chemistry, Manufacturing and Controls plan for its lead drug candidate, Menerba®, in a Type “B” or “End of Phase 2” meeting. A copy of this press release is furnished as Exhibit 99.1 to this Current Report.

 

Item 9.01. Financial Statements and Exhibits.

 

    (d)     Exhibits.

 

   

Exhibit
Number

        
  99.1    Press Release, dated September 23, 2010, entitled “FDA Approves Manufacturing Plan for Menerba, Bionovo’s Menopausal Hot Flash Drug Candidate”

 

1


SIGNATURES

  Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    Bionovo, Inc.
Date: September 27, 2010     By:  

/s/ Isaac Cohen

      Isaac Cohen
      Chairman and Chief Executive Officer

 

2


EXHIBIT INDEX

 

99.1    Press Release, dated September 23, 2010, entitled “FDA Approves Manufacturing Plan for Menerba, Bionovo’s Menopausal Hot Flash Drug Candidate”